Author:
Gottlieb Alice B.,Burge Russel,Malatestinic William N.,Zhu Baojin,Zhao Yunyang,McCormack Julie,Kimel Miriam,Merola Joseph F.
Publisher
Springer Science and Business Media LLC
Reference24 articles.
1. Kimel M, Bell JA, Sexton C, Revicki DA. HRQL outcomes for assessing effectiveness in clinical trials of biological agents for psoriasis: a systematic review. Adv Psor Inflam Skin Dis. 2009;1(1):7–14.
2. Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–72.
3. Armstrong AW, Siegel MP, Bagel J, Boh EE, Buell M, Cooper KD, et al. From the Medical Board of the National Psoriasis Foundation: treatment targets for plaque psoriasis. J Am Acad Dermatol. 2017;76(2):290–8.
4. Liu L, Lu J, Allan BW, Tang Y, Tetreault J, Chow CK, et al. Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A. J Inflamm Res. 2016;9:39–50.
5. Food and Drug Administration. Ixekizumab prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125521s024lbl.pdf.